Home LiteratureArticle Details
PMID: 23401782 Published · ppublish English Journal Article

Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines.

International journal of breast cancer ·Vol. 2013 ·2013-00-00 ·Pages 872743

Barnabas N, Cohen D

Abstract

We reviewed the phenotypic and molecular characteristics of MCF10DCIS.com and the SUM cell lines based on numerous studies performed over the years. The major signaling pathways that give rise to the phenotype of these cells may serve as a good resource of information when researchers in drug discovery and development use these cells to identify novel targets and biomarkers. Major signaling pathways and mutations affecting the coding sequence are also described providing important information when using these cells as a model in a variety of studies.

Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Barnabas Nandita
Asterand US, 440 Burroughs, Tech One Building, Suite 501, Detroit, MI 48202-3420, USA.
Cohen Dalia
References (104)
104 references, click to expand
  1. Mutations truncating the EP300 acetylase in human cancers.
    Nat Genet. 2000 Mar;24(3):300-3 PMID: 10700188
  2. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  3. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Breast Cancer Res Treat. 2012 Apr;132(3):937-45 PMID: 21701879
  4. Human breast cancer cell lines as models of growth regulation and disease progression.
    J Mammary Gland Biol Neoplasia. 1996 Jan;1(1):111-21 PMID: 10887484
  5. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.
    Hum Mol Genet. 1998 May;7(5):801-5 PMID: 9536083
  6. Human tumor suppressor ARF impedes S-phase progression independent of p53.
    Cancer Res. 2002 Feb 15;62(4):1171-7 PMID: 11861400
  7. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
    Med Oncol. 2011 Sep;28(3):745-52 PMID: 20405247
  8. Estrogen induces stromal cell-derived factor 1 (SDF-1/CXCL12) production in human endometrial stromal cells: a possible role of endometrial epithelial cell growth.
    Fertil Steril. 2011 Jan;95(1):444-7 PMID: 20869048
  9. RAS oncogenes: weaving a tumorigenic web.
    Nat Rev Cancer. 2011 Oct 13;11(11):761-74 PMID: 21993244
  10. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.
    Nature. 2007 Oct 11;449(7163):682-8 PMID: 17898713
  11. Targeting the mitogen-activated protein kinase cascade to treat cancer.
    Nat Rev Cancer. 2004 Dec;4(12):937-47 PMID: 15573115
  12. The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis.
    Oncogene. 2010 Nov 4;29(44):5883-94 PMID: 20697354
  13. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media.
    Cancer Res. 1993 Feb 1;53(3):627-35 PMID: 8425198
  14. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.
    Mol Endocrinol. 2003 May;17(5):792-803 PMID: 12586845
  15. Novel image analysis approach quantifies morphological characteristics of 3D breast culture acini with varying metastatic potentials.
    J Biomed Biotechnol. 2012;2012:102036 PMID: 22665978
  16. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.
    Cancer Res. 2001 Oct 15;61(20):7642-6 PMID: 11606406
  17. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.
    Oncogene. 2006 Sep 25;25(43):5864-74 PMID: 16998501
  18. Chek2 DNA damage response pathway and inherited breast cancer risk.
    J Clin Oncol. 2011 Oct 1;29(28):3813-5 PMID: 21876079
  19. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival.
    PLoS One. 2010 Apr 20;5(4):e10240 PMID: 20421921
  20. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
    Oncogene. 2010 Sep 16;29(37):5193-203 PMID: 20581867
  21. Synthetic lethality--a new direction in cancer-drug development.
    N Engl J Med. 2009 Jul 9;361(2):189-91 PMID: 19553640
  22. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
    Breast Cancer Res Treat. 2006 Feb;95(3):219-28 PMID: 16244790
  23. Biology of the p21-activated kinases.
    Annu Rev Biochem. 2003;72:743-81 PMID: 12676796
  24. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
    Lancet. 2010 Jul 24;376(9737):235-44 PMID: 20609467
  25. Molecular interactions in cancer cell metastasis.
    Acta Histochem. 2010;112(1):3-25 PMID: 19162308
  26. What is triple-negative breast cancer?
    Eur J Cancer. 2008 Dec;44(18):2799-805 PMID: 19008097
  27. Knockdown of Sec6 improves cell-cell adhesion by increasing α-E-catenin in oral cancer cells.
    FEBS Lett. 2012 Mar 23;586(6):924-33 PMID: 22381337
  28. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.
    Nature. 2001 Sep 20;413(6853):316-22 PMID: 11565034
  29. The PI3K pathway as drug target in human cancer.
    J Clin Oncol. 2010 Feb 20;28(6):1075-83 PMID: 20085938
  30. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.
    Cancer Biol Ther. 2008 Nov;7(11):1774-82 PMID: 18787417
  31. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling.
    Cancer Res. 2001 Jan 1;61(1):278-84 PMID: 11196175
  32. Molecular cytogenetic analysis of 11 new breast cancer cell lines.
    Br J Cancer. 1999 Dec;81(8):1328-34 PMID: 10604729
  33. Comprehensive molecular portraits of human breast tumours.
    Nature. 2012 Oct 4;490(7418):61-70 PMID: 23000897
  34. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines.
    Breast Cancer Res. 2010;12(5):R87 PMID: 20964822
  35. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.
    Clin Cancer Res. 2010 Feb 1;16(3):876-87 PMID: 20103682
  36. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer.
    Mol Pharmacol. 2011 Mar;79(3):360-7 PMID: 21115634
  37. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control.
    Nature. 2004 Aug 12;430(7001):797-802 PMID: 15306814
  38. Regulation of cadherin-mediated adhesion in morphogenesis.
    Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34 PMID: 16025097
  39. Role of p53 in Cell Death and Human Cancers.
    Cancers (Basel). 2011 Mar 03;3(1):994-1013 PMID: 24212651
  40. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.
    Exp Mol Pathol. 2006 Oct;81(2):115-22 PMID: 16919268
  41. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
    Cancer Res. 2010 Mar 15;70(6):2485-94 PMID: 20215504
  42. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.
    Cell Cycle. 2010 Oct 15;9(20):4153-63 PMID: 20948315
  43. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.
    Cancer Res. 1997 Mar 1;57(5):978-87 PMID: 9041204
  44. Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB).
    J Biol Chem. 2011 Jun 17;286(24):21814-25 PMID: 21515682
  45. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes.
    Cancer Lett. 2012 Jun 1;319(1):49-55 PMID: 22202642
  46. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Mol Cancer Ther. 2011 Mar;10(3):558-65 PMID: 21216929
  47. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.
    Oncogene. 2012 Jan 26;31(4):403-18 PMID: 21765476
  48. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Adv Cancer Res. 2010;108:73-112 PMID: 21034966
  49. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
    Blood. 2006 Mar 1;107(5):1761-7 PMID: 16269611
  50. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
    Nat Med. 2009 Aug;15(8):907-13 PMID: 19648928
  51. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ.
    J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6 PMID: 10904098
  52. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
    Breast Cancer Res Treat. 2010 May;121(1):53-64 PMID: 19593635
  53. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
    Breast Cancer Res Treat. 2006 Sep;99(1):97-101 PMID: 16541312
  54. Microenvironmental regulation of metastasis.
    Nat Rev Cancer. 2009 Apr;9(4):239-52 PMID: 19279573
  55. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
    Nat Rev Cancer. 2011 Apr;11(4):254-67 PMID: 21390059
  56. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
    Ann Oncol. 2011 Mar;22(3):515-523 PMID: 20603440
  57. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures.
    Breast Cancer Res Treat. 2010 Aug;122(3):795-801 PMID: 20571867
  58. CD44 is of functional importance for colorectal cancer stem cells.
    Clin Cancer Res. 2008 Nov 1;14(21):6751-60 PMID: 18980968
  59. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts.
    Int J Cancer. 2007 May 15;120(10):2127-34 PMID: 17266026
  60. Targeted therapies for breast cancer.
    J Clin Invest. 2011 Oct;121(10):3797-803 PMID: 21965336
  61. The retinoblastoma protein and cell cycle control.
    Cell. 1995 May 5;81(3):323-30 PMID: 7736585
  62. Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.
    Mol Cell Pharmacol. 2012 Jan 1;4(1):31-40 PMID: 24558516
  63. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
    Oncologist. 2011;16 Suppl 1:12-9 PMID: 21278436
  64. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
    Mol Cancer Res. 2007 Feb;5(2):195-201 PMID: 17314276
  65. Tumours with PI3K activation are resistant to dietary restriction.
    Nature. 2009 Apr 9;458(7239):725-31 PMID: 19279572
  66. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    J Thorac Oncol. 2010 May;5(5):649-57 PMID: 20354454
  67. Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
    N Engl J Med. 2011 Jan 20;364(3):205-14 PMID: 21208101
  68. Metastatic behavior of breast cancer subtypes.
    J Clin Oncol. 2010 Jul 10;28(20):3271-7 PMID: 20498394
  69. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.
    Cancer Res. 2009 Feb 15;69(4):1302-13 PMID: 19190339
  70. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.
    Mol Biol Cell. 2007 Jan;18(1):76-83 PMID: 17065554
  71. Heterogeneity in breast cancer.
    J Clin Invest. 2011 Oct;121(10):3786-8 PMID: 21965334
  72. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer.
    J Proteome Res. 2007 Aug;6(8):2993-3002 PMID: 17608509
  73. The cell-cell adhesion molecule E-cadherin.
    Cell Mol Life Sci. 2008 Nov;65(23):3756-88 PMID: 18726070
  74. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin.
    J Cell Mol Med. 2010 Jun;14(6B):1693-706 PMID: 19538464
  75. CD44: from adhesion molecules to signalling regulators.
    Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 PMID: 12511867
  76. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.
    Breast Cancer Res. 2011;13(6):R115 PMID: 22093547
  77. Tailoring to RB: tumour suppressor status and therapeutic response.
    Nat Rev Cancer. 2008 Sep;8(9):714-24 PMID: 19143056
  78. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
    Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5025-30 PMID: 11309506
  79. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
    Cancer Res. 2006 Jan 1;66(1):41-5 PMID: 16397213
  80. Nuclear signalling by tumour-associated antigen EpCAM.
    Nat Cell Biol. 2009 Feb;11(2):162-71 PMID: 19136966
  81. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.
    Cell Stem Cell. 2011 Feb 4;8(2):149-63 PMID: 21295272
  82. p21-activated kinases in cancer.
    Nat Rev Cancer. 2006 Jun;6(6):459-71 PMID: 16723992
  83. Overcoming radiation resistance in inflammatory breast cancer.
    Cancer. 2010 Jun 1;116(11 Suppl):2840-5 PMID: 20503417
  84. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
    Breast Cancer Res Treat. 2009 Jan;113(2):285-91 PMID: 18297428
  85. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells.
    Cell. 2011 Aug 19;146(4):633-44 PMID: 21854987
  86. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
    Cancer Cell. 2006 Dec;10(6):515-27 PMID: 17157791
  87. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
    Cancer Treat Rev. 2012 Feb;38(1):68-75 PMID: 21576002
  88. Phosphatidylinositol 3-kinase: the oncoprotein.
    Curr Top Microbiol Immunol. 2010;347:79-104 PMID: 20582532
  89. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
    Nature. 1994 Apr 21;368(6473):753-6 PMID: 8152487
  90. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.
    Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7177-82 PMID: 21482786
  91. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    J Clin Pathol. 2011 Nov;64(11):937-46 PMID: 21680574
  92. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
    Curr Stem Cell Res Ther. 2009 Jan;4(1):50-60 PMID: 19149630
  93. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    J Clin Oncol. 2011 Feb 1;29(4):398-405 PMID: 21172893
  94. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.
    Clin Cancer Res. 2010 Jan 1;16(1):45-55 PMID: 20028757
  95. Galectin-3--a jack-of-all-trades in cancer.
    Cancer Lett. 2011 Dec 27;313(2):123-8 PMID: 21974805
  96. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Cancer Res. 2005 Apr 1;65(7):2554-9 PMID: 15805248
  97. Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer.
    Expert Rev Anticancer Ther. 2011 Aug;11(8):1193-6 PMID: 21916572
  98. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.
    Breast Cancer Res. 2008;10(5):R75 PMID: 18782450
  99. Cyclin D1 in breast cancer pathogenesis.
    J Clin Oncol. 2005 Jun 20;23(18):4215-24 PMID: 15961768
  100. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    J Clin Oncol. 2010 Jun 1;28(16):2698-704 PMID: 20421541
  101. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
    J Clin Invest. 2011 Jul;121(7):2723-35 PMID: 21633165
  102. Live or let die: the cell's response to p53.
    Nat Rev Cancer. 2002 Aug;2(8):594-604 PMID: 12154352
  103. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
    Cancer Cell. 2011 Oct 18;20(4):472-86 PMID: 22014573
  104. Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations.
    Breast Cancer Res Treat. 2010 Jul;122(1):125-33 PMID: 19763817
Article Info
Journal
International journal of breast cancer
Abbr.
Int J Breast Cancer
ISSN
2090-3170
DOI
10.1155/2013/872743
Published
2013-00-00
Epub
2013-00-16
Pages
872743
Language
English
Region
Egypt
NLM ID
101568103
PMCID
PMC3562669
External Links
PubMed source DOI: 10.1155/2013/872743 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2